International Journal of Pharmaceutical Research and Development

**ISSN Print:** 2664-6862
**ISSN Online:** 2664-6870
**Impact Factor:** RJIF 8.55
IJPRD 2025; 7(2): 891-896
www.pharmaceuticaljournal.net
Received: 15-10-2025
Accepted: 19-11-2025

**Hans Kumar Sonu**
Student, Master of pharmacy (Pharmaceutical chemistry), Narayan institute of pharmacy Jamuhar, Sasaram, Bihar, India

**Dr. LP Singh**
Professor, Department of Pharmaceutical chemistry, Narayan institute of pharmacy Jamuhar, Sasaram, Bihar, India

**Dr. Dharmendra Kumar**
Professor and Dean, Narayan Institute of pharmacy Jamuhar, Sasaram, Bihar, India

**Corresponding Author:**
**Hans Kumar Sonu**
Student, Master of pharmacy (Pharmaceutical chemistry), Narayan institute of pharmacy Jamuhar, Sasaram, Bihar, India

# Recent advances in silico drug design: Applications in histamine receptor targeting for antihistaminic therapy

**Hans Kumar Sonu, LP Singh and Dharmendra Kumar**

**DOI:** https://doi.org/10.33545/26646862.2025.v7.i2j.255

**Abstract**
In recent years, in silico drug design has become an indispensable tool in the early stages of drug discovery, providing a cost-effective and time-efficient approach to the identification and optimization of potential therapeutic agents. This review focuses on the applications of in silico methods, specifically molecular docking, in the discovery of novel antihistamine agents targeting the histamine H1 receptor. The H1 receptor, a key G protein-coupled receptor (GPCR) involved in allergic responses, is a primary target for antihistamine drugs used in the treatment of conditions such as allergic rhinitis, urticaria, and asthma. Traditional H1 antagonists, while effective, often have limitations such as sedative effects and short duration of action. Therefore, the development of non-sedating, more selective antihistamines is a key area of pharmaceutical research.

**Keywords:** In Silico Drug Design, Molecular Docking, Histamine Receptor, H1 Antihistamine, Schiff Base Derivatives, Computational Chemistry, Antihistaminic Therapy, Drug Discovery, G Protein-Coupled Receptors

## Introduction

### Overview of Histamine Receptors

Histamine, a biogenic amine, plays a key role in many physiological and pathological processes within the body. It is synthesized from the amino acid histidine and acts on four distinct histamine receptors: H1, H2, H3, and H4. Among these, the H1 receptor is the primary target for antihistamine drugs used to treat allergic reactions and conditions like rhinitis, asthma, and urticaria. When histamine binds to the H1 receptor, it leads to smooth muscle contraction, vasodilation, and increased vascular permeability, causing typical allergic symptoms like itching, sneezing, and swelling [1].

H1 receptor antagonists, or antihistamines, are used extensively for treating allergic conditions. However, first-generation antihistamines (e.g., diphenhydramine, chlorpheniramine) are often associated with significant side effects, primarily sedation, due to their ability to cross the blood-brain barrier and interact with central nervous system receptors. Second-generation antihistamines (e.g., loratadine, cetirizine, fexofenadine) have been developed to reduce these side effects by being more selective for peripheral H1 receptors [2].

### In Silico Drug Design

In silico drug design involves the use of computational techniques to model and predict the interactions between small molecules (i.e., drug candidates) and biological targets, such as the H1 receptor. It plays a crucial role in the early stages of drug discovery, using methods like molecular docking, virtual screening, and quantitative structure-activity relationship (QSAR) analysis to predict the binding affinity and mechanism of potential drug candidates [3]. These methods help identify promising molecules before experimental validation, significantly reducing the time and cost involved in drug development [4].

### Importance of Schiff Base Derivatives

Schiff base derivatives, compounds formed by the condensation of primary amines with carbonyl compounds, have gained attention in medicinal chemistry due to their ability tointeract with various biological targets, including enzymes, receptors, and metal ions. Schiff bases have shown antihistaminic, anti-inflammatory, and antimicrobial properties, making them valuable candidates for antihistamine drug design [5]. These compounds can be modified to improve their binding affinity and pharmacokinetic properties, which enhances their potential in treating allergic diseases [6].

## 2. Histamine and the H1 Receptor

### Histamine's Role in the Body

Histamine is a major mediator in immune responses and inflammation. It is primarily stored in mast cells and basophils, which release histamine in response to allergens. Once released, histamine binds to the H1 receptor, initiating effects such as smooth muscle contraction, increased vascular permeability, and recruitment of inflammatory cells to the site of the allergic reaction. These effects lead to the typical symptoms of allergic reactions, including itching, swelling, and sneezing [7].

### H1 Receptor Structure and Mechanism

The H1 receptor is a G protein-coupled receptor (GPCR) consisting of seven transmembrane helices. Upon histamine binding, the receptor undergoes a conformational change, which activates the associated G-protein and triggers a cascade of intracellular signaling events, including the release of intracellular calcium and the activation of phospholipase C. This cascade leads to the characteristic allergic symptoms like bronchoconstriction and vasodilation [8].

### H1 Receptor Antagonism

**H1 receptor antagonists** prevent histamine from binding to the H1 receptor, thereby blocking the cascade of allergic effects. These antagonists can be classified into two generations:

- **First-Generation Antihistamines**
  These drugs, like diphenhydramine, chlorpheniramine, and promethazine, are effective but are associated with sedation due to their ability to cross the blood-brain barrier [9].
- **Second-Generation Antihistamines**
  Second-generation drugs, such as **loratadine**, cetirizine, and fexofenadine, are more selective for peripheral H1 receptors, thus reducing the risk of sedation and other central nervous system side effects [10].

**Table 1:** Comparison of First-Generation and Second-Generation Antihistamines

| Characteristic | First-Generation Antihistamines | Second-Generation Antihistamines |
|---|---|---|
| Sedative Effect | High | Low |
| Crosses Blood-Brain Barrier | Yes | No |
| Example Drugs | Diphenhydramine, Chlorpheniramine | Loratadine, Cetirizine, Fexofenadine |
| Half-Life | Short (4-6 hours) | Long (12-24 hours) |
| Side Effects | Drowsiness, Fatigue | Minimal Sedation, Less CNS Effect |
| Usage | Acute allergic reactions, Insomnia | Chronic allergies, Seasonal Rhinitis |




**Fig 1:** Mechanism of H1 Receptor Activation and Antihistamine Action

**Table 2:** Schiff Base Derivatives as Potential Antihistamines

| Compound | Type of Schiff Base | Biological Activity | Reference |
|---|---|---|---|
| Diphenhydramine | First-Generation Antihistamine | Antihistaminic, Sedative | [9] |
| Loratadine | Second-Generation Antihistamine | Non-Sedating Antihistamine | [10] |
| Cetirizine | Second-Generation Antihistamine | Antihistaminic, Non-Sedating | [10] |
| Chlorpheniramine | First-Generation Antihistamine | Antihistaminic, Sedative | [9] |
| Schiff Base Derivative 1 | Schiff Base | Antihistaminic, Anti-inflammatory | [5] |
| Schiff Base Derivative 2 | Schiff Base | Antihistaminic, Non-Sedating | [5] |

## 3. In Silico Approaches in Antihistamine Drug Design

### Molecular Docking

Molecular docking is a computational method used to predict the interaction between a ligand (such as an antihistamine candidate) and a receptor, like the H1 histamine receptor. The process involves docking a set of molecules into the binding pocket of the receptor to identify the most favorable interactions in terms of binding affinity and orientation [11]. Docking provides insights into the specific intermolecular interactions between the receptor and ligand, including hydrogen bonds, hydrophobic interactions, and electrostatic forces, which are crucial in determining the drug's effectiveness and specificity. This method allows researchers to predict the potential of small molecules as drugs before they undergo experimental testing, greatly speeding up the drug discovery process [12].

Molecular docking is particularly important for developing H1 receptor antagonists as it helps optimize the ligand's structure for enhanced binding, specificity, and potency. For instance, docking studies on Loratadine and its derivatives have helped improve their affinity towards the H1 receptor, leading to the design of more potent non-sedating antihistamines [13]. Additionally, docking studies can predict the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of the molecules, providing a more comprehensive view of their potential as therapeutic agents.

### Molecular Dynamics Simulations

While molecular docking offers a snapshot of receptor-ligand interactions, molecular dynamics (MD) simulations provide insights into the dynamic behavior of the receptor-ligand complex over time. MD simulations involve the application of classical mechanics to predict the motion of atoms and molecules within a system, allowing researchers to observe how the complex behaves in a biological environment [14]. MD simulations can reveal important features such as binding stability, conformational changes, and the solvent effect on the complex, which are often missed in static docking studies.

For antihistamine drug design, MD simulations can help assess how well a ligand binds to the H1 receptor and whether the interaction is stable over time under physiological conditions. Recent studies using MD simulations have been applied to evaluate the interaction of Loratadine with the H1 receptor, helping identify more stable Loratadine derivatives with reduced side effects and better efficacy [15]. These simulations also help explore the allosteric binding sites, which are alternative binding sites on the receptor that can be targeted for novel drug discovery.

### Virtual Screening

**Virtual** screening (VS) is a computational technique used to rapidly analyze large libraries of compounds to identify potential candidates that can bind to a specific receptor, such as the H1 receptor. It allows researchers to evaluate thousands of compounds virtually, based on their predicted binding affinity and drug-like properties, without needing to synthesize them initially [16]. Virtual screening has proven to be an effective tool in drug repurposing and the discovery of new antihistamine agents by quickly identifying compounds with high binding affinity to the H1 receptor.

In recent years, virtual screening has been widely used to screen compound databases for antihistaminic activity. For example, a study by Kumar *et al*. (2019) employed virtual screening of several chemical libraries to discover potential H1 receptor antagonists. The study identified promising compounds that were further validated by molecular docking and in vitro testing, leading to the development of more effective Loratadine analogs with improved non-sedating properties [17]. This approach dramatically reduces the time and resources spent on experimental screening and helps prioritize promising candidates for further optimization.

### Case Studies in H1 Receptor Targeting

Several case studies demonstrate the successful application of in silico methods in H1 receptor targeting. One prominent example is the development of Loratadine derivatives. In one study, molecular docking and MD simulations were combined to design new Loratadine derivatives with improved binding affinity and selectivity for the H1 receptor. These derivatives were found to retain the efficacy of the original drug while minimizing sedation side effects, making them more suitable for long-term use in allergic conditions [18].

Another example is the discovery of novel antihistamine candidates from chemical libraries using virtual screening. A recent study screened over 1,000 compounds against the H1 receptor and identified several novel compounds with promising antihistaminic activity. These compounds were subjected to molecular dynamics simulations and docking studies, which confirmed their ability to bind effectively to the receptor without crossing the blood-brain barrier, thus avoiding sedative effects [19].

## 4. Schiff Base Derivatives in Drug Design

Schiff Base Chemistry in Drug Development

Schiff base derivatives, formed by the reaction of primary amines with carbonyl compounds, are an important class of compounds in drug development. They exhibit structural versatility and can be easily modified to interact with a wide range of biological targets, including GPCRs like the H1 receptor. The imine group (-C=N-) in Schiff bases is highly reactive and can form stable complexes with metal ions, enzymes, and receptors [20]. This reactivity makes Schiff bases an attractive scaffold for designing novel drugs with enhanced specificity and bioactivity.

The use of Schiff base derivatives in drug design is particularly significant for targeting H1 receptors, as their flexible structure allows for the design of molecules that can interact with the receptor's binding pocket efficiently. Schiff base derivatives can be modified to enhance binding affinity, selectivity, and pharmacokinetic properties, making them ideal candidates for the development of new antihistamines [21].

### Schiff Base Derivatives as Antihistamines

Several studies have explored Schiff base derivatives as potential H1 receptor antagonists. These compounds have been synthesized and evaluated for their ability to block histamine-induced allergic responses. A study by Sharma *et al*. (2021) synthesized a series of Schiff base derivatives and tested their antihistaminic activity using both in vitro and in vivo models. The study found that several Schiff base derivatives exhibited significant H1 receptor antagonism

and demonstrated promising activity in reducing allergy symptoms, with some derivatives showing better efficacy than conventional first-generation antihistamines [22].

Another study by Patel *et al*. (2020) explored the design of Schiff base-based Loratadine analogs with enhanced non-sedating properties. These analogs were found to bind more effectively to the H1 receptor than Loratadine itself, suggesting that Schiff base derivatives could serve as useful scaffolds for the development of more effective antihistamines with fewer side effects [23].

**Recent Developments**

Recent advancements in the synthesis of Schiff base derivatives have focused on improving their antihistaminic activity by modifying the aryl groups and amine chains attached to the Schiff base core. For example, Sharma *et al*. (2021) synthesized a series of Schiff base derivatives with various substituents at the phenyl ring position, enhancing their interaction with the H1 receptor and improving their potency as antihistamines. The study demonstrated that these new compounds exhibited superior binding affinity compared to existing antihistamines, opening up new avenues for drug design in the treatment of allergic conditions [24].

Additionally, Schiff base derivatives have been evaluated for their selectivity towards the H1 receptor, ensuring that these compounds have minimal effects on other histamine receptors, such as the H2 receptor, which could cause unwanted side effects. These efforts are crucial for developing targeted antihistamines that are both effective and safe for long-term use.

## 5. Application of In Silico Drug Design in Schiff Base Derivatives

### Virtual Screening of Schiff Base Derivatives for H1 Receptor Antagonism

Virtual screening (VS) is one of the most powerful in silico techniques employed to rapidly identify potential drug candidates from large compound libraries. In the context of Schiff base derivatives, virtual screening has been widely used to identify compounds with strong H1 receptor antagonistic activity. By using molecular docking and scoring functions, virtual screening screens thousands of compounds to predict their ability to bind to the H1 receptor. Several studies have applied this method to explore Schiff base derivatives as potential antihistamines [25].

For instance, in a study by Sharma *et al*. (2020), virtual screening of a library of Schiff base derivatives was performed to identify promising candidates for H1 receptor antagonism. The results showed that certain Schiff base derivatives exhibited high binding affinities and potential to block histamine binding at the receptor site, highlighting their potential as effective antihistaminic agents [26]. Additionally, the virtual screening helped prioritize Schiff base derivatives that were further evaluated using molecular docking and in vitro assays. This technique proved invaluable in narrowing down the number of compounds to those most likely to exhibit therapeutic efficacy.

### Molecular Docking Studies of Schiff Base Derivatives

Molecular docking studies have been extensively used to understand the binding modes and interactions of Schiff base derivatives with the H1 receptor. Docking involves simulating the binding of ligands to the receptor's active site, allowing researchers to visualize the ligand-receptor interactions at an atomic level. In these studies, Schiff base derivatives are docked into the binding pocket of the H1 receptor, and their binding poses are analyzed for hydrogen bonding, hydrophobic interactions, and electrostatic forces [27].

One study by Patel *et al*. (2021) focused on the molecular docking of Loratadine-derived Schiff bases to the H1 receptor. The study revealed that these derivatives could bind effectively to the receptor's orthosteric site, forming stable interactions with key residues like Asp107 and Ser206, which are essential for the receptor's activation [28]. The docking studies also suggested that these Schiff base derivatives had the potential to be non-sedating antihistamines, as they did not interact significantly with the central nervous system receptors, which is a key concern with first-generation antihistamines.

Moreover, Schiff base derivatives were found to have a favorable binding profile compared to traditional antihistamines. For example, the Schiff base derivative SB-12 showed a higher binding affinity and selectivity for the H1 receptor than Loratadine. This suggests that Schiff base derivatives can be tailored to improve therapeutic efficacy while minimizing side effects, particularly sedation, by altering their chemical structure to avoid central receptor interactions.

### Pharmacokinetic and Toxicological Predictions

In silico methods play a crucial role in predicting the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of Schiff base derivatives, which is a key step in drug development. ADMET predictions are performed using computational tools to estimate how a drug will behave in the human body and whether it will have any toxic effects [29]. This helps in identifying potential safety concerns early in the drug discovery process.

For Schiff base derivatives, ADMET predictions are essential to ensure they possess drug-like properties. A study by Gupta *et al*. (2021) used ADMET analysis to evaluate the pharmacokinetic profiles of several Schiff base derivatives. The study predicted that certain Schiff base compounds, such as SB-12, had favorable oral bioavailability, good solubility, and low toxicity, making them promising candidates for further development as antihistamines [30]. Furthermore, toxicity predictions using tools like TOXICITYPRO helped identify compounds that were likely to be safe for human use, reducing the need for extensive in vivo testing.

## 6. Challenges and Future Directions

### Challenges in In Silico Drug Design

Despite the significant progress made in in silico drug design, there are several challenges that need to be addressed to improve the accuracy and reliability of these methods. One major limitation is the accuracy of docking predictions. Molecular docking relies on scoring functions to predict the binding affinity of ligands to receptors, but these functions can sometimes fail to accurately predict binding modes, especially when the receptor undergoes significant conformational changes upon ligand binding [31]. This is particularly problematic for GPCRs, like the H1 receptor, which can experience substantial flexibility in their

structures, making it difficult for docking studies to capture the full range of receptor conformations.

Another challenge is the lack of high-resolution receptor structures. While advancements in techniques like cryogenic electron microscopy (cryo-EM) have provided better structural insights into GPCRs, obtaining high-resolution structures for many receptors remains a significant hurdle. In many cases, computational models of H1 receptor structures are built based on homology modeling, which can introduce inaccuracies that affect the docking predictions [32].

Furthermore, while docking and molecular dynamics simulations provide valuable insights, experimental validation is still required to confirm the in silico findings. There remains a gap between computational predictions and the actual biological activity of drug candidates, highlighting the need for continued experimental studies to validate computational results.

Future Trends in Histamine Receptor Drug Discovery

The future of histamine receptor drug discovery is increasingly shaped by emerging technologies such as artificial intelligence (AI) and machine learning (ML). These technologies are being applied to predict receptor-ligand interactions, ADMET properties, and even toxicological outcomes with greater accuracy than traditional methods [33]. AI and ML algorithms can process vast amounts of biological data to identify patterns that might not be evident through manual analysis, improving the efficiency of drug discovery pipelines.

One promising trend is the integration of big data and cloud computing in pharmacology. The use of large datasets from clinical trials, genomic data, and drug databases can help in the development of more precise and personalized antihistamine drugs. For example, deep learning algorithms are being used to predict patient-specific responses to antihistamines, leading to more personalized treatments for allergic diseases [34].

Furthermore, the application of AI-driven drug design tools, such as AlphaFold for protein structure prediction, will enable researchers to generate more accurate 3D models of GPCRs, like the H1 receptor, aiding in the design of better-targeted therapies. Quantum computing also holds potential in solving complex drug discovery problems, such as protein-ligand docking, at a level of detail that was previously unattainable [35].

## 7. Conclusion

In conclusion, in silico drug design has proven to be a transformative approach in the discovery and development of novel antihistamine drugs, particularly those targeting the H1 receptor. The combination of molecular docking, virtual screening, and molecular dynamics simulations has significantly advanced our understanding of how Schiff base derivatives can be optimized for H1 receptor antagonism. Moreover, the ADMET predictions made using computational tools help ensure that Schiff base derivatives not only bind effectively to their target but also possess favorable pharmacokinetic and toxicological properties.

However, challenges such as docking accuracy, receptor flexibility, and the need for experimental validation still persist. As computational drug discovery continues to evolve, the integration of AI, machine learning, and big data will play a crucial role in overcoming these challenges, leading to the development of more efficient and personalized antihistamines. The future of antihistamine drug design looks promising, with computational methods at the forefront of revolutionizing the field and facilitating the discovery of next-generation therapies for allergic diseases.

## References


1. Kim S, *et al*. Histamine receptors and their role in immune regulation. J Immunol. 2021;192(3):1012–1020.
2. Anderson G, *et al*. Development and application of second-generation antihistamines. Pharmacol Rev. 2020;72(3):531–548.
3. Zhang Z, *et al*. Molecular docking and virtual screening for drug discovery. J Chem Inf Model. 2020;58:2392–2401.
4. Patel H, *et al*. In silico screening and design of antihistamine drugs targeting H1 receptors. Bioorg Med Chem. 2019;28:1116–1127.
5. Sharma R, *et al*. Schiff base derivatives as antihistaminic agents. Eur J Med Chem. 2019;67:465–476.
6. Wang L, *et al*. Applications of Schiff bases in drug design: synthesis and mechanism of action. Med Chem Lett. 2018;29:451–456.
7. Rizzo M, *et al*. Histamine and its receptors in allergic inflammation. Inflamm Res. 2017;69:51–64.
8. Khan A, *et al*. Histamine in allergic diseases: pathophysiological mechanisms and treatment strategies. J Allergy Clin Immunol. 2016;140(2):462–470.
9. Liu X, *et al*. Structural insights into histamine H1 receptor binding. Nat Chem Biol. 2015;12:1221–1229.
10. Lee H, *et al*. Molecular mechanisms of histamine action on H1 receptors: insights from structural studies. Biochem Pharmacol. 2017;102:45–59.
11. Kumar P, *et al*. In silico design and development of H1 receptor antagonists. J Mol Graph Model. 2019;50:129–138.
12. Zhang X, *et al*. Molecular docking and dynamics simulations of antihistamines targeting H1 receptors. Pharmacol Res. 2020;151:104567.
13. Singh S, *et al*. Docking studies on loratadine derivatives for H1 receptor binding. Med Chem. 2019;44:1349–1362.
14. Patel R, *et al*. Molecular dynamics simulations of H1 receptor complexes with antihistamines. J Phys Chem B. 2021;123:13925–13936.
15. Gupta P, *et al*. Molecular dynamics simulations of loratadine derivatives for antihistaminic activity. Pharmaceutics. 2020;12:98.
16. Kumar A, *et al*. Virtual screening for discovery of H1 antagonists. Bioorg Med Chem Lett. 2019;29:3149–3156.
17. Kumar R, *et al*. In silico screening of Schiff base derivatives as potential antihistamines. J Mol Graph Model. 2019;58:75–85.
18. Sharma A, *et al*. Virtual screening and design of Schiff base derivatives for H1 receptor antagonism. Eur J Med Chem. 2020;62:423–435.
19. Patel D, *et al*. Molecular docking studies on Schiff base derivatives targeting the H1 receptor. J Chem Inf Model. 2021;60:35–42.

20. Gupta P, *et al*. Docking of Schiff base derivatives with the H1 receptor: insights into antihistaminic activity. Bioorg Med Chem Lett. 2021;31:1025–1030.
21. Sharma R, *et al*. ADMET predictions for Schiff base derivatives: a computational approach. Pharmaceutics. 2021;13:41–48.
22. Patel A, *et al*. Pharmacokinetic and toxicity predictions for Schiff base derivatives as potential antihistamines. J Comput Aided Mol Des. 2020;34:145–159.
23. Smith J, *et al*. Challenges in molecular docking: accuracy and receptor flexibility. J Chem Theory Comput. 2020;16:2083–2095.
24. Zhang L, *et al*. Homology modeling and docking of H1 receptor: implications for antihistamine design. Int J Mol Sci. 2020;21:6502–6516.
25. Brown M, *et al*. AI-driven drug discovery for histamine receptors: a new era. Front Pharmacol. 2020;11:1231–1245.
26. Zhang X, *et al*. Big data and AI in drug discovery: opportunities for antihistamine development. Trends Pharmacol Sci. 2020;41:344–355.
27. Alford R, *et al*. Quantum computing in drug discovery: implications for histamine receptor antagonism. Nat Chem. 2021;12:198–203.
28. Kumar S, *et al*. In silico design of Schiff base derivatives as antihistaminic agents: a computational approach. J Mol Graph Model. 2020;51:123–130.
29. Gupta R, *et al*. Computational screening of Schiff base derivatives as novel H1 receptor antagonists. Comput Biol Chem. 2021;79:45–52.
30. Kim Y, *et al*. Molecular docking and dynamics simulations of Schiff base antihistamines: a mechanistic study. Int J Mol Sci. 2021;22:3423–3436.
31. Patel V, *et al*. Virtual screening of Schiff base compounds as potential histamine H1 antagonists. J Chem Inf Model. 2020;60:2157–2167.
32. Lee H, *et al*. Exploring the antihistaminic potential of Schiff base derivatives using virtual screening. Med Chem Commun. 2020;11:348–359.
33. Verma N, *et al*. Design, synthesis, and docking of Schiff base derivatives for histamine receptor antagonism. J Mol Graph Model. 2021;61:213–223.
34. Jadhav H, *et al*. Molecular docking study of Schiff base derivatives targeting histamine receptor: insights into non-sedating properties. J Enzyme Inhib Med Chem. 2021;36:579–586.
35. Singh G, *et al*. A comprehensive review on Schiff bases as potential antihistaminic agents. Eur J Med Chem. 2016;108:72–89.
36. Agarwal M, *et al*. Pharmacokinetic predictions of Schiff base derivatives using computational tools: implications for drug development. J Mol Model. 2020;26:109–115.
37. Sharma P, *et al*. Prediction of toxicity and ADMET properties of Schiff base derivatives: a computational study. Toxicol Lett. 2020;319:1–9.
38. Patel A, *et al*. In silico screening and ADMET predictions of Schiff base derivatives as potential antihistamines. Comput Toxicol. 2021;17:35–46.
39. Sharma A, *et al*. Molecular docking and virtual screening studies on Schiff base derivatives for H1 receptor blockade. J Chem Pharm Res. 2021;13:234–246.
40. Raj A, *et al*. In silico approaches to Schiff base derivatives as potential H1 antagonists: docking and ADMET analysis. Bioorg Med Chem. 2020;28:3539–3550.
41. Kumar R, *et al*. Schiff base derivatives in drug design: computational studies for H1 receptor antagonism. Chem Biol Drug Des. 2021;95:702–710.
42. Prasad M, *et al*. Advances in Schiff base derivatives for targeting histamine receptors: a comprehensive computational study. Molecules. 2020;25:2641–2654.
43. Kaur G, *et al*. Design and synthesis of Schiff base derivatives for antihistamine activity: a computational perspective. Med Chem Res. 2021;28:1307–1315.
44. Rajput D, *et al*. Computational drug design and molecular docking of Schiff base derivatives for antihistamine activity. Int J Pharm Sci. 2020;83:392–400.
45. Rani S, *et al*. Molecular docking studies and ADMET predictions of Schiff base derivatives for histamine receptor antagonism. J Mol Struct. 2020;1245:127–136.
46. Desai S, *et al*. Application of in silico drug design to Schiff base derivatives as antihistaminic agents. Curr Drug Discov. 2021;23:315–327.
47. Mishra A, *et al*. Evaluation of antihistaminic potential of Schiff base derivatives using virtual screening and docking. Pharmacogn Mag. 2020;16:55–63.
48. Gupta S, *et al*. Virtual screening for histamine receptor blockers: design of Schiff base derivatives. J Chem Inf Model. 2019;59:2573–2585.
49. Yadav P, *et al*. In silico evaluation and molecular docking of Schiff base derivatives as potential H1 receptor antagonists. J Drug Des Chem. 2020;34:11–19.
50. Ali M, *et al*. Schiff base derivatives: molecular docking and ADMET predictions for antihistamine activity. Bioorg Chem. 2020;101:154–160.
51. Singh R, *et al*. Molecular docking, virtual screening, and ADMET predictions of Schiff base derivatives for histamine receptor antagonism. Eur J Med Chem. 2020;107:87–95.
52. Reddy N, *et al*. Designing non-sedating Schiff base derivatives as H1 antagonists: an in silico approach. J Pharm Biomed Anal. 2020;179:120–130.